The Court found that the scheme of birth registration for the children of trans men is lawful and proportionate. The Government welcomes the Court\u2019s decision.<\/p>
The Government\u2019s view is that the judgment has no effect on the availability of regulated fertility treatment and will now consider whether there should be further guidance to clarify this position. The Government considers that regulated fertility treatment is currently, and will remain, equally available to all (trans) women and (trans) men under the Human Fertilisation and Embryology Acts.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"} } , "answeringMemberPrinted" : {"_value" : "Baroness Blackwood of North Oxford"} , "dateOfAnswer" : {"_value" : "2019-10-25", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "HL6"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-10-25T11:54:37.72Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-10-14", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Fertility: Medical Treatments"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government what assessment they have made of the impact of the judgment in R (TT) v the Registrar General for England and Wales & Ors [2019] EWHC 2384 (Fam) on the (1) Human Fertilisation and Embryology Act 2008, and (2) regulation of fertility treatment by the Human Fertilisation and Embryology Authority.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/2501", "label" : {"_value" : "Biography information for Baroness Barker"} } , "tablingMemberPrinted" : [{"_value" : "Baroness Barker"} ], "uin" : "HL5"} , {"_about" : "http://data.parliament.uk/resources/1149714", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1149714/answer", "answerText" : {"_value" : "
Following Royal Assent for the Mental Capacity (Amendment) Act 2019, the Department has been engaging across England and Wales with a range of key stakeholders from the health and social care sector and people with lived experience to co-produce the Code of Practice for the new Liberty Protection Safeguards. We plan to start public consultation in the new year and the Code will be laid before both Houses ahead of the new Liberty Protection Safeguards system coming into force.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"} } , "answeringMemberPrinted" : {"_value" : "Baroness Blackwood of North Oxford"} , "dateOfAnswer" : {"_value" : "2019-10-25", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-10-25T11:55:05.753Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-10-14", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Mental Capacity: Codes of Practice"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government when consultation on the Code of Practice issued under the Mental Capacity (Amendment) Act 2019 will commence.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/2501", "label" : {"_value" : "Biography information for Baroness Barker"} } , "tablingMemberPrinted" : [{"_value" : "Baroness Barker"} ], "uin" : "HL7"} , {"_about" : "http://data.parliament.uk/resources/1149756", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1149756/answer", "answerText" : {"_value" : "
NHS England and NHS Improvement are providing \u2018pump prime\u2019 funding to 12 pilot sites over 2019/20 and 2020/21 to test and implement new models of integrated primary and community mental health care for adults and older adults with a range of severe mental illnesses. Eight of these will test models that include services for adult eating disorders, including:<\/p>
- Cambridgeshire and Peterborough Sustainability and Transformation Partnership;<\/p>
- Cheshire and Merseyside Sustainability and Transformation Partnership;<\/p>
- Herefordshire and Worcestershire Sustainability and Transformation Partnership;<\/p>
- Hertfordshire and West Essex Sustainability and Transformation Partnership;<\/p>
- North East London Sustainability and Transformation Partnership;<\/p>
- North West London Sustainability and Transformation Partnership;<\/p>
- Somerset Sustainability and Transformation Partnership; and<\/p>
- South Yorkshire and Bassetlaw Integrated Care System<\/p>
These sites will work towards improving access to care for adults and older adults with eating disorders in line with published guidance from NHS England and NHS Improvement. They will also generate the first phase of learning about how to achieve greater levels of parity with children and young people\u2019s eating disorder services over the course of the NHS Long Term Plan.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"} } , "answeringMemberPrinted" : {"_value" : "Baroness Blackwood of North Oxford"} , "dateOfAnswer" : {"_value" : "2019-10-25", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-10-25T11:55:40.41Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-10-14", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Eating Disorders: Mental Health Services"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government, following their response to the Seventeenth Report of Session 2017\u201319 by the House of Commons Public Administration and Constitutional Affairs Committee (HC855) on 23 September, how many sites have been selected to \"pump prime\" innovative models of service for adults with eating disorders; and where those test sites will be.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4178", "label" : {"_value" : "Biography information for Baroness Parminter"} } , "tablingMemberPrinted" : [{"_value" : "Baroness Parminter"} ], "uin" : "HL49"} , {"_about" : "http://data.parliament.uk/resources/1149773", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1149773/answer", "answerText" : {"_value" : "
Most new medicines are assessed by the National Institute for Health and Care Excellence (NICE) which makes recommendations for the National Health Service on whether they represent a clinically and cost effective use of NHS resources. Since 2016, NICE makes recommendations for the NHS on all new licensed cancer medicines through its technology appraisal programme. NHS commissioners are legally required to fund treatments recommended in NICE technology appraisal guidance.<\/p>
NICE has appraised Avastin (bevacizumab) for use in the treatment of a number of different types of cancer and has unfortunately not been able to recommend it as a clinically and cost effective use of NHS resources for any type of cancer at the price offered by the drug company. Avastin is not therefore routinely funded by the NHS for any licensed indication.<\/p>
Avastin is funded as an off-label treatment for some types of cancer through the Cancer Drugs Fund.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"} } , "answeringMemberPrinted" : {"_value" : "Baroness Blackwood of North Oxford"} , "dateOfAnswer" : {"_value" : "2019-10-25", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-10-25T11:56:13.193Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-10-14", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Bevacizumab"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government why Avastin is not routinely made available on the NHS for certain groups of cancer patients.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4151", "label" : {"_value" : "Biography information for Lord Willis of Knaresborough"} } , "tablingMemberPrinted" : [{"_value" : "Lord Willis of Knaresborough"} ], "uin" : "HL66"} , {"_about" : "http://data.parliament.uk/resources/1149774", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1149774/answer", "answerText" : {"_value" : "
Avastin has approval from the European Medicines Agency to be used to treat cancer in combination with specific chemotherapies in the advanced stages of several cancers. They are:<\/p>
- Metastatic colorectal cancer;<\/p>
- Metastatic breast cancer;<\/p>
- Certain types of unresectable advanced, metastatic or recurrent lung cancer;<\/p>
- Advanced or metastatic renal cell cancer;<\/p>
- Advanced or recurrent or resistant ovarian/fallopian tube cancer; and<\/p>
- Persistent or recurrent or metastatic cervical cancer.<\/p>
Full details of the indications that Avastin is licensed for can be found in the European public assessment report for Avastin. It explains how the Agency assessed the medicine to recommend its authorisation and its conditions of use and is publicly available on their website.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"} } , "answeringMemberPrinted" : {"_value" : "Baroness Blackwood of North Oxford"} , "dateOfAnswer" : {"_value" : "2019-10-25", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-10-25T12:00:04.5Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-10-14", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Bevacizumab"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government whether Avastin has approval from the European Medicines Authority to be used to treat cancer.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4151", "label" : {"_value" : "Biography information for Lord Willis of Knaresborough"} } , "tablingMemberPrinted" : [{"_value" : "Lord Willis of Knaresborough"} ], "uin" : "HL67"} , {"_about" : "http://data.parliament.uk/resources/1149777", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1149777/answer", "answerText" : {"_value" : "
The National Institute for Health and Care Excellence has not produced any guidance relating to combined liver and bowel transplants for cancer patients.<\/p>
The Department funds research mainly through the National Institute for Health Research (NIHR). The usual practice of the NIHR and other research funders is not to ring-fence funds for expenditure on particular topics. The NIHR welcomes funding applications for research into any aspect of human health, including liver and bowel transplantation.<\/p>
There has been one relevant clinical trial that reached Phase 3:<\/p>
Study title: In open, prospective, single arm study investigating efficacy and safety of human hepatitis B immunoglobulin Zutectra in liver transplanted patients - the ZEUS Study.<\/p>
Date: 22 November 2012 \u2013 10 April 2014<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"} } , "answeringMemberPrinted" : {"_value" : "Baroness Blackwood of North Oxford"} , "dateOfAnswer" : {"_value" : "2019-10-25", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-10-25T11:56:33.353Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-10-14", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Cancer: Transplant Surgery"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government whether liver and bowel transplantation is currently approved by the National Institute for Health and Care Excellence for cancer patients; and if not, whether there are any clinical trials that have reached Phase 3.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4151", "label" : {"_value" : "Biography information for Lord Willis of Knaresborough"} } , "tablingMemberPrinted" : [{"_value" : "Lord Willis of Knaresborough"} ], "uin" : "HL70"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 6, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }